|Last Update: 05/22/13 - 2:16 PM EDT|
|YTD Performance: 14.42%|
|Previous Close: $118.65|
|52 Week Range: $98.79 - $121.33|
|Oustanding Shares: 94,039,071|
|Market Cap: 11,193,470,621|
|Qtr (06/13)||Qtr (09/13)||FY (06/13)||FY (06/14)|
|Number of Analysts||16||8||16||16|
|Growth Rate (Year over Year)||23.10%||15.94%||12.53%||17.95%|
PRGO was initiated with a Market Perform rating, said Leerink. Valuation is fair based on stable fundamentals and store brand expansion plans. Price target is $124.
PRGO was upgraded from Neutral to Overweight, JP Morgan said. Company has multiple growth drivers in place.
Beating the S&P 500 ETF's five-plus-year round trip to record levels.
PRGO was upgraded to Buy from Neutral, UBS said. $130 price target. Greater confidence in growth.
The generic drugmaker shows new signs of life after months of struggle.
PRGO was upgraded from Equal-weight to Overweight, Morgan Stanley said. $125 price target. Nutritionals overhang has been lifted and the company has strong growth prospects.
PRGO was downgraded from Neutral to Sell, Goldman Sachs said. $110 price target. Growth could slow in the next few quarters.
PRGO was downgraded from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.
PRGO was upgraded from Market Perform to Outperform, Barrington said. $142 price target. Company can continue to leverage its competitive advantages.
Now is the time to pop the pharmaceutical pill and buy.